MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	2/26/2007 11:24:11 AM
	of 1826

These EPS revisions from Merrill seem significant to me .I don't own MOGN Quarterly Breakout We have updated our model with a quarterly breakout and raised our ’07 estimates. We project ‘07 Dacogen sales of $99 MM vs. guidance of $90 MM - $100 MM. We continue to project ’07 Aloxi sales of $250 MM. Aloxi quarterly run rate: We expect Aloxi to begin growing again in 2Q07 as Aloxi’s profitability to doctors surpasses that for generic Zofran. Our quarterly Aloxi sales estimates are $47 MM sales in 1Q07, $56 MM in 2Q07, $70 MM in 3Q07, and $77 MM in 4Q07. Adjustments from initial ’07 estimates: We tightened our Dacogen estimates slightly to $99 MM from $104 MM as we refined our ’07 model. COGS and income taxes were lowered on company guidance. In addition, to be more conservative, we lowered our Aquavan estimates. Revised EPS estimates: We have increased our ’07 non-GAAP EPS (ex-options) estimate to $0.57 from $0.34 based on lower than expected spending. But, due to lower Aquavan estimates, we decreased our ’08 estimate to $0.92 from $1.09 and our ’09 estimate to $1.01 from $1.37.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next